You are here: Industry Insights > CKD

News List

A Brief Discussion on Roxadustat in the Midst of the Controversy zhulikou431
August 31, 2021
Recently, there is a good news for roxadustat, which is in the midst of the controversy. On August 19, 2021 local time, Astellas Pharma Inc. and FibroGen jointly announced that roxadustat was approved by the European Commission (EC) for adult patients.
Timely intervention: First chronic kidney disease treatment in 20 years pharmatimes
February 03, 2022
Significant landmark as NICE recommends AstraZeneca's chronic kidney disease treatment Forxiga.
Baxter Indonesia launches My Kidney Journey portal to support patients with Chronic Kidney Disease prnasia
November 16, 2021
Baxter Asia Pacific (Baxter), a global leader in dialysis care, announced today the launch of My Kidney Journey (www.infoginjal.com), a comprehensive online portal to support patients living with Chronic Kidney Disease (CKD) in Indonesia.
NICE recommend dapagliflozin for treating chronic kidney disease EuropeanPharmaceuticalReview
November 09, 2021
The National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin as an option for treating certain individuals with chronic kidney disease (CKD) in new draft guidance.
US clears Cara, Vifor's Korsuva to treat itching in CKD patients firstwordpharma
August 24, 2021
Cara Therapeutics and Vifor Pharma said Monday that the FDA has approved Korsuva (difelikefalin) to treat moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis.
US rejects AZ and FibroGen’s anaemia drug roxadustat pharmatimes
August 13, 2021
The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat.
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease drugs
August 12, 2021
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD).
Update on US Regulatory Review of Roxadustat in Anaemia of Chronic Kidney Disease americanpharmaceuticalreview
August 12, 2021
The US FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis dependent (NDD) and dialysis-dependent (DD) adult patients.
Forxiga Approved in EU to Treat Chronic Kidney Disease americanpharmaceuticalreview
August 10, 2021
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease pharmatimes
August 09, 2021
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the European Commission for the treatment of chronic kidney disease (CKD) in the European Union (EU).

Previous page 1 2 3 4 5 6 Next page